Nuveen LLC Sells 17,721 Shares of Danaher Corporation $DHR

Nuveen LLC trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,583,145 shares of the conglomerate’s stock after selling 17,721 shares during the quarter. Nuveen LLC owned 0.79% of Danaher worth $1,278,094,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. JPL Wealth Management LLC bought a new stake in shares of Danaher during the third quarter worth $25,000. Elevated Capital Advisors LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $26,000. WFA of San Diego LLC bought a new stake in shares of Danaher in the second quarter valued at about $26,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Danaher in the third quarter valued at about $27,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $27,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on DHR shares. UBS Group decreased their price objective on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Argus decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Friday, April 24th. The Goldman Sachs Group decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Monday, April 13th. Wells Fargo & Company decreased their price objective on Danaher from $240.00 to $212.00 and set an “equal weight” rating for the company in a report on Wednesday, April 22nd. Finally, Jefferies Financial Group restated a “buy” rating and issued a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $233.61.

Danaher Stock Performance

Shares of Danaher stock opened at $180.65 on Friday. The company has a market capitalization of $127.86 billion, a PE ratio of 34.94, a P/E/G ratio of 2.45 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The company has a 50-day simple moving average of $181.15 and a two-hundred day simple moving average of $204.96. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm’s revenue was up 3.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.88 earnings per share. Research analysts expect that Danaher Corporation will post 8.43 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher’s payout ratio is currently 30.95%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.